Emalex Biosciences Announces First Patient Enrolled in Phase 2b Clinical Study to Evaluate the Efficacy ...
(WorldNews Business)

CHICAGO--(BUSINESS WIRE)--Aug 14, 2019-- Emalex Biosciences, Inc., a biopharmaceutical company developing innovative therapies for patients with neurological and psychiatric conditions, announced today that the first patient was recently enrolled in the company´s international Phase 2b study to evaluate the efficacy and safety of ecopipam HCl tablets in children and adolescents with Tourette Syndrome (TS). Ecopipam is an investigational drug that selectively blocks the actions of dopamine at the D1 receptor. The Phase 2b clinical study of ecopipam in children and adolescent patients (aged >6 to <18 years) with TS is being conducted in multiple centers in the United States, Canada, and...